Board Selects New CEO Erik Kinnman to Lead NeuroVive

NeuroVive Pharmaceutical AB (publ) board of directors is pleased to announce
that it has selected Erik Kinnman as NeuroVive’s Chief Executive Officer (CEO).
Erik Kinnman will assume the new role on the 14th March 2016, leaving Chief
Medical Officer (CMO) and Chief Operating Officer (COO) roles within his own
consultancy business.
Erik Kinnman is a seasoned life science executive with broad experience and
understanding from the industry across a variety of businesses and functions. He
has held a number of senior leadership positions in biopharmaceutical companies
such as AstraZeneca and Sobi. His expertise and experience includes clinical
development, business strategy, business development, and investor relations.
Erik Kinnman also has experience from the financial sector. In addition, he
holds an Executive MBA from the Stockholm School of Economics and has
comprehensive scientific qualifications from the Karolinska Institutet, which
has rendered him a Ph.D. and an Associate Professor. Moreover, Erik Kinnman is
an M.D., board certified in Neurology and Pain Management.

“The NeuroVive Board and I are confident that Erik Kinnman is the right person
to lead the company, its strategy, and leverage the opportunities. The
combination of his strategic vision and medical expertise is an excellent fit
with NeuroVive’s strategy refocused towards R&D. Erik Kinnman is a strong and
experienced leader who has a proven ability to translate scientific, clinical
and business strategy into execution," commented Gregory Batcheller, Chairman of
the NeuroVive Board of Directors. "He will provide expertise and focus across
the organization and establish solid partnerships that will enhance our R&D
program further. His broad experience grounded in research, medicine and the
biopharmaceutical industry is exactly what we need to lead this organization
forward.”

“I am excited about NeuroVive, the CEO role, and the opportunity to contribute
to the success and growth of the company. NeuroVive is a highly innovative
organization and I am convinced that it has great potential in its range of
novel treatment opportunities and their commercial potential. NeuroVive and its
partners are truly led by a purpose and passion to make a difference and
meaningful impact to patients affected by mitochondrial disorders. I will enable
our researchers and partners to deliver on the opportunities in the clinical
projects, as well as in the early pipeline to drive the value of NeuroVive.”
says Erik Kinnman.

Erik Kinnman succeeds interim CEO Jan Nilsson, who will resume his position as
Chief Operating Officer for NeuroVive.  Jan has made significant contributions
to move the organization forward. The recent partnership deals with both
Isomerase and the University of Pennsylvania (UPENN) have been significant
achievements under Jan’s leadership.  Jan’s extensive NeuroVive knowledge and
commitment to move the organization forward have been greatly appreciated by
both the teams and board of NeuroVive.

About NeuroVive
NeuroVive Pharmaceutical AB (publ) is a pioneer in mitochondrial medicine and a
company committed to the discovery and development of highly targeted candidates
that preserve mitochondrial integrity and function in areas of significant
therapeutic need. NeuroVive’s business approach is driven by value-adding
partnerships with mitochondrial research institutions and commercial partners
across the globe. NeuroVive’s portfolio consists of two clinical projects in
acute kidney injury (AKI) and traumatic brain injury (TBI) with candidates in
clinical and preclinical development and two drug discovery platforms. The
NeuroSTAT® product has orphan drug status in Europe and in the US for treatment
of moderate to severe traumatic brain injury and is currently being evaluated in
a study, CHIC. Ciclosporin is being evaluated in an on-going study, CiPRICS, in
acute kidney injury during major surgery. NeuroVive’s shares are listed on
Nasdaq, Stockholm, Sweden.

For investor relations and media questions, please contact:
Christine Tadgell, NeuroVive, Tel: +46 (0)275 62 20 or ir@neurovive.com
It is also possible to arrange an interview with NeuroVive’s Chairman Gregory
Batcheller at the above contacts.

NeuroVive Pharmaceutical AB (publ)
Medicon Village, SE-223 81 Lund, Sweden
Tel: +46 (0)46 275 62 20 (switchboard), Fax: +46 (0)46 888 83 48
info@neurovive.com, www.neurovive.com

NeuroVive Pharmaceutical AB (publ) is required to publish the information in
this news release under The Swedish Securities Market Act. The information was
submitted for publication on 23 February 2016, at 08 30 CET.
NeuroVive Pharmaceutical AB (publ) - the mitochondrial medicine company. The
company is listed on NASDAQ OMX Stockholm, Small Cap, under the ticker symbol
NVP. The share is also traded on the OTC market in the US. NeuroVive
Pharmaceutical (OTC: NEVPF) trades on the OTC Pink Market. Investors can find
Real-Time quotes and market information for the company
at www.otcmarkets.com/stock/NEVPF/quote (http://htt://www.otcmarkets.com/stock/N
E 
VPF/quot)